Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial

PURPOSE: Patients with metastasized breast cancer often suffer from discomfort caused by metastatic bone disease. Thus, osteoprotection is an important part of therapy in breast cancer metastasized to bone, and bisphosphonates (BPs) are a major therapeutic option. In this study, our objectives were...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: von Au, Alexandra, Milloth, Eva, Diel, Ingo, Stefanovic, Stefan, Hennigs, Andre, Wallwiener, Markus, Heil, Joerg, Golatta, Michael, Rom, Joachim, Sohn, Christof, Schneeweiss, Andreas, Schuetz, Florian, Domschke, Christoph
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944913/
https://ncbi.nlm.nih.gov/pubmed/27468239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S103130
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars